Canadian Cancer Trials Group
ctg.queensu.caLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
92
Active
53
Phase 3
21
Total enrollment
26,769
Pipeline matrix
Showing 40 of 85 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexamethasone | — | — | 6 | ||||
| Docetaxel | — | — | — | — | 4 | ||
| Pembrolizumab | — | — | — | — | 5 | ||
| Carboplatin | — | — | — | 5 | |||
| Darolutamide | — | — | — | — | 2 | ||
| Ipatasertib | — | — | — | — | 2 | ||
| Fulvestrant | — | — | — | — | 2 | ||
| ADT | — | — | — | — | — | 2 | |
| Leucovorin | — | — | — | — | — | 1 | |
| Oxaliplatin | — | — | — | — | — | 1 | |
| Fluoruracil | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | — | — | 1 | |
| Memantine | — | — | — | — | — | 1 | |
| Intermittent PD-1 inhibitor therapy | — | — | — | — | — | 1 | |
| Continuous PD-1 inhibitor therapy | — | — | — | — | — | 1 | |
| Abiraterone | — | — | — | — | — | 1 | |
| Enzalutamide | — | — | — | — | — | 1 | |
| Apalutamide | — | — | — | — | — | 1 | |
| MEDI4736 | — | — | — | — | — | 1 | |
| Daratumumab | — | — | — | — | — | 1 | |
| Lenalidomide | — | — | — | — | — | 1 | |
| Isatuximab | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | 13 | ||
| Cisplatin | — | — | 10 | ||||
| Tremelimumab | — | — | — | — | 8 | ||
| Gemcitabine | — | — | — | 7 | |||
| CFI-400945 | — | — | — | — | — | 4 | |
| Rituximab | — | — | — | — | 3 | ||
| Paclitaxel | — | — | — | — | 6 | ||
| Cyclophosphamide | — | — | — | — | 3 | ||
| Temsirolimus | — | — | — | — | 3 | ||
| CFI-402257 | — | — | — | — | — | 2 | |
| Palbociclib | — | — | — | — | — | 2 | |
| Sunitinib | — | — | — | — | — | 2 | |
| Ibrutinib | — | — | — | — | — | 2 | |
| RP-6306 | — | — | — | — | — | 2 | |
| RP-3500 | — | — | — | — | — | 2 | |
| MG1MA3 | — | — | — | — | — | 1 | |
| AdMA3 | — | — | — | — | — | 1 | |
| Adavosertib | — | — | — | — | — | 1 |
45 more active programs hidden
Next readouts
- 2015-07-06
- 2018-07-20
- 2019-09-19
- 2020-02-24
- 2022-04-29
- 2022-09-15
- 2022-11-21
- 2024-06-25
- 2024-10-07
- 2025-05-23
Top conditions
- Breast Cancer9
- Prostate Cancer7
- Cancer5
- Colorectal Cancer4
- Chronic Lymphocytic Leukemia3
- Multiple Myeloma3
- Rectal Cancer2
- Metastatic Breast Cancer2
Frequently asked questions about Canadian Cancer Trials Group
- How many clinical trials does Canadian Cancer Trials Group have on ClinicalTrials.gov?
- Canadian Cancer Trials Group is listed as the lead sponsor on 92 clinical trials in ClinicalTrials.gov, 53 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Canadian Cancer Trials Group's trials are in Phase 3?
- 21 of Canadian Cancer Trials Group's trials are in Phase 3, spread across 85 active drug programs.
- What therapeutic areas does Canadian Cancer Trials Group focus on?
- Canadian Cancer Trials Group's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Cancer, Colorectal Cancer, Chronic Lymphocytic Leukemia.
- When are Canadian Cancer Trials Group's next clinical trial readouts?
- Canadian Cancer Trials Group has 10 upcoming primary-completion readouts tracked here; the soonest is “A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours”, expected around 2015-07-06.